A pharmacoeconomic analysis using Asian cohort data from the INAVO120 trial concluded that inavolisib plus palbociclib/fulvestrant is not cost-effective nationally in China despite a 61% negotiated price reduction. The analysis suggested affordability may improve only in wealthier provinces. The result highlights how pricing and reimbursement hurdles can constrain oncology uptake even when clinical benefits are established. It also underscores the need for developers to plan health-economic evidence generation early, not just clinical efficacy. For biotech strategy teams, the take-away is that launch readiness increasingly includes payer-aligned economic positioning and region-specific cost thresholds.